Loring Wolcott & Coolidge Fiduciary Advisors’s GSK GSK Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.8K	Hold	760	–	–	﹤0.01%	454
2026 Q1	$44.2K	Hold	760	–	–	﹤0.01%	431
2025 Q4	$38.6K	Hold	760	–	–	﹤0.01%	434
2025 Q3	$34.6K	Hold	760	–	–	﹤0.01%	452
2025 Q2	$29.2K	Hold	760	–	–	﹤0.01%	428
2025 Q1	$28.1K	Hold	760	–	–	﹤0.01%	421
2024 Q4	$27K	Hold	760	–	–	﹤0.01%	441
2024 Q3	$28.7K	Sell	760 -1,420	-65%	-$58.1K	﹤0.01%	429
2024 Q2	$84.8K	Hold	2,180	–	–	﹤0.01%	348
2024 Q1	$88.5K	Sell	2,180 -229	-10%	-$9.44K	﹤0.01%	346
2023 Q4	$95K	Hold	2,409	–	–	﹤0.01%	353
2023 Q3	$82.3K	Sell	2,409 -4,609	-66%	-$164K	﹤0.01%	377
2023 Q2	$250K	Buy	+7,018	New	+$252K	﹤0.01%	270
2022 Q4	–	Sell	-7,864	Closed	-$231K	–	589
2022 Q3	$231K	Hold	7,864	–	–	﹤0.01%	271
2022 Q2	$428K	Hold	7,864	–	–	0.01%	219
2022 Q1	$428K	Sell	7,864 -11,176	-59%	-$607K	﹤0.01%	226
2021 Q4	$1.05M	Buy	19,040 +3,304	+21%	+$172K	0.01%	171
2021 Q3	$752K	Sell	15,736 -2,432	-13%	-$122K	0.01%	189
2021 Q2	$904K	Sell	18,168 -3,769	-17%	-$181K	0.01%	180
2021 Q1	$979K	Sell	21,937 -6,809	-24%	-$309K	0.01%	158
2020 Q4	$1.32M	Buy	28,746 +36	+0.1%	+$1.65K	0.01%	140
2020 Q3	$1.35M	Buy	28,710 +27,950	+3,678%	+$1.4M	0.02%	127
2020 Q2	$39K	Hold	760	–	–	﹤0.01%	398
2020 Q1	$36K	Hold	760	–	–	﹤0.01%	408
2019 Q4	$45K	Hold	760	–	–	﹤0.01%	426
2019 Q3	$41K	Hold	760	–	–	﹤0.01%	424
2019 Q2	$38K	Sell	760 -200	-21%	-$10K	﹤0.01%	429
2019 Q1	$50K	Hold	960	–	–	﹤0.01%	407
2018 Q4	$46K	Hold	960	–	–	﹤0.01%	423
2018 Q3	$48K	Sell	960 -200	-17%	-$10.2K	﹤0.01%	428
2018 Q2	$58K	Hold	1,160	–	–	﹤0.01%	414
2018 Q1	$57K	Hold	1,160	–	–	﹤0.01%	431
2017 Q4	$51K	Hold	1,160	–	–	﹤0.01%	430
2017 Q3	$59K	Sell	1,160 -1,539	-57%	-$78.1K	﹤0.01%	409
2017 Q2	$137K	Buy	2,699 +51	+2%	+$2.72K	﹤0.01%	313
2017 Q1	$140K	Sell	2,648 -195	-7%	-$9.89K	﹤0.01%	312
2016 Q4	$137K	Hold	2,843	–	–	﹤0.01%	308
2016 Q3	$153K	Sell	2,843 -12	-0.4%	-$658	﹤0.01%	290
2016 Q2	$155K	Sell	2,855 -48	-2%	-$2.53K	﹤0.01%	279
2016 Q1	$147K	Hold	2,903	–	–	﹤0.01%	273
2015 Q4	$146K	Sell	2,903 -400	-12%	-$20.4K	﹤0.01%	294
2015 Q3	$172K	Hold	3,303	–	–	﹤0.01%	292
2015 Q2	$172K	Sell	3,303 -200	-6%	-$11.3K	﹤0.01%	292
2015 Q1	$202K	Hold	3,503	–	–	0.01%	282
2014 Q4	$187K	Sell	3,503 -400	-10%	-$22.4K	﹤0.01%	285
2014 Q3	$224K	Hold	3,903	–	–	0.01%	256
2014 Q2	$261K	Buy	3,903 +120	+3%	+$8.12K	0.01%	243
2014 Q1	$253K	Sell	3,783 -140	-4%	-$9.46K	0.01%	244
2013 Q4	$262K	Sell	3,923 -100	-2%	-$6.48K	0.01%	237
2013 Q3	$252K	Sell	4,023 -885	-18%	-$57K	0.01%	229
2013 Q2	$307K	Buy	+4,908	New	+$312K	0.01%	224

Other funds holding GSK

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

MHI

Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's GSK Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its GSK (GSK) position steady in Q2 2026 at 760 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in GSK in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.35M in Q3 2020. 599 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 760 shares of GSK worth $39.8K as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors left its GSK share count unchanged in Q2 2026.
GSK made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #454 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in GSK in Q2 2013 and has held it in 51 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's GSK position peaked at $1.35M in Q3 2020.
599 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.